Table 2. Overall 5-year survival of GNB and NB patients categorized by clinical-pathological features and Gal-3 expression.

	KM 5-year survival, %	Patients	Deaths	P
Age (months)
<15	87.2	39	5	<0.001
≥15	40.3	84	49
aTotal		123
Sex
M	57.2	59	25	0.73
F	53.5	64	29
aTotal		123
Primary site
Adrenal	56.4	58	25	0.96
Nonadrenal	54.3	65	29
aTotal		123
Stage
1-2-4s	91.5	47	4	<0.001
3-4	32.2	76	50
aTotal		123
(INPC) Tumor histology
NB	51.9	104	49	0.07
GNB	73.7	19	5
aTotal		123
dNB	78.2	25	5	<0.001
pdNB	50.2	61	30
udNB	22.2	18	14
aTotal		104
(INPC) Shimada
Favorable	83.9	71	11	<0.001
Unfavorable	16.2	52	43
aTotal		123
Mycn
Nonamplified	74.5	89	22	<0.001
Amplified	6.5	31	29
Total		120
Gal-3
Negative	48.4	99	50	0.003
Positive	83.3	24	4
aTotal		123

Statistically significant values are in bold

^aGN is not included because it is benign by definition